Thrombosis risk assessment may predict clinical presentation and length of hospital stay in covid-19 pneumonia

The severe acute respiratory distress syndrome related to coronavirus-2 (SARS-CoV-2) and its clinical presentation as Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, Hubei, China in December 2019. It has spread rapidly from its origin in Wuhan City to other countries of the world over the last several months.

Although it mainly affects the respiratory system, multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. SARS-CoV-2 infection may also lead to thrombotic disease both in the venous and arterial circulation of patients apart from the respiratory system due to excessive inflammation, thrombocyte activation, endothelial malfunction, and stasis.

Investigators have reported that both CHADS2 and CHA2DS2-VASc scores were related to mortality in individuals that had stable coronary angina, acute coronary syndrome, Takotsubo syndrome or sick sinus syndrome, apart from atrial fibrillation. In addition, thrombocyte/lymphocyte (PLT/LYM) and neutrophil/lymphocyte (NEU/LYM) ratios on admission were also related to thromboembolic complications in former studies which found them useful in predicting the prognosis of acute pulmonary embolism, as being one of the thromboembolic complications of Covid-19.

Investigators suggest that the parameters mentioned above should also be studied in terms of thrombotic complications of Covid-19. Thus they aimed to find out potential associations between markers of prothrombotic or inflammatory conditions and some clinical features of Covid-19 pneumonia cases on admission and follow-up.

Observational retrospective cohort study

Sampling Method: Non-Probability Sample
Study Population: Patients with COVID-19 pneumonia diagnosed in the emergency, internal medicine, and cardiology outpatient clinics will be included
 

Inclusion Criteria:

• patients diagnosed with COVID-19 pneumonia between March 11th, 2020, and April 25th, 2020 in the emergency, internal medicine, and cardiology outpatient clinics.
• patients diagnosed by PCR testing and computed tomography of the chest

Exclusion Criteria:

• patients below 18 years of age
• patients with an alternative etiology of pneumonia

Primary Outcome Measures  :

• length of hospital stay [ Time Frame: 2 months ]
• from admission to discharge expressed in days

ClinicalTrials.gov Identifier: NCT04423315

Vulnerable Populations

Jun 2020 — Jul 2020

Turkey